Lipocine announced that it has filed suit against Clarus Therapeutics in the United States District Court of Delaware alleging that Clarus’s Jatenzo product infringes six of Lipocine’s U.S. patents: 9,034,858; 9,205,057; 9,480,690; 9,757,390; 6,569,463; and 6,923,988. “We have invested significant resources in developing innovations that have led to our importantly held strong intellectual property rights. We will defend those rights when infringed upon,” said Lipocine CEO Mahesh Patel.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.